Acquisition will extend the company's leadership in ophthalmic medical devices market and expands its position in the vitreo-retinal surgery segment D.O.R.C., a leading player in the retinal surgical ...

In the first three months of the new financial year, the company recorded revenues of EUR 219.0m (previous year: EUR 210.3m) and EBIT of EUR 31.2m (previous year: EUR 28.3m). The EBIT margin improved ...

Carl Zeiss Meditech is a subsidiary of Carl Zeiss AG and manufactures tools for eye examination and medical lasers. The company has a strong financial performance with high gross and net margins.

Fintel reports that on August 6, 2024, MWB RESEARCH AG upgraded their outlook for Carl Zeiss Meditec AG - Depositary Receipt () (OTCPK:CZMWY) from Hold to Buy. As of August 6, 2024, the average ...

Read Carl Zeiss Meditec AG I (AFX.BE) Q2 FY2025 earnings call transcript on Yahoo Finance to keep your investing strategy up to date with all of the latest information ...

Please provide your email address to receive an email when new articles are posted on . The stolen Zeiss files acquired by Topcon included highly confidential information. Topcon has agreed to pay a ...

Christian Müller, PhD, is leaving Carl Zeiss Meditec AG’s management board to serve as Carl Zeiss AG’s CFO. 1. Dr. Müller served as Carl Zeiss Meditec AG’s CFO since 2009. 2. He came to Carl Zeiss in ...

Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care. JENA, Germany, Aug. 21, 2025 ...

LONDON (Reuters) – Optics specialist Carl Zeiss AG is poised to prop up its eyeglass lens maker Carl Zeiss Vision with a second equity injection which will dilute the shareholding of private equity ...

Hello ladies and gentlemen and welcome to the Carl Zeiss Meditec AG Analyst Conference Call for the Six Months Results 2023/2024. At this time, all participants have been placed on a listen-only mode.

Earnings call Carl Zeiss Meditec reported H1 FY2024/25 revenue of €1.051B, up 10.9% YoY, with Q2 accelerating to 19% growth. Order intake surged 33.4% YoY. EBITA margin stabilized at 10.8%, aided by ...